Please assess the completion status of the following clinical trial:

Trial Title: Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 9 to 11 years (children), 12 to 17 years (adolescents), or 18 to 60 years (adults) on the day of inclusion~* For child/adolescent subjects, informed consent form has been signed and dated by the parent(s) (and subject, if applicable by local regulations), or another legally acceptable representative (and independent witness, if required by local regulations), and the assent form has been signed and dated by the subject (if applicable by the local Ethics Committee or country regulations). For adult subjects, informed consent form has been signed and dated by the subject (and an independent witness, if required by local regulations).~* Subject/subject and parent/legally acceptable representative is/are able to attend all scheduled visits and to comply with all trial procedures~* Covered by health insurance, if required by local regulation.~Exclusion Criteria:~* Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination and until at least 4 weeks after vaccination)~* Participation at the time of study enrollment or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure~* Receipt of any vaccine in the 4 weeks preceding trial vaccination or planned receipt of any vaccine in the 3 weeks following trial vaccination~* Previous vaccination against influenza with the 2012 Southern Hemisphere formulation or the 2011-2012 Northern Hemisphere formulation in the previous 6 months with either the trial vaccine or another vaccine~* Receipt of immune globulins, blood or blood-derived products in the past 3 months~* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)~* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances~* Self-reported thrombocytopenia, contraindicating intramuscular vaccination based on investigator's judgment~* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on investigator's judgment~* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily~* Current alcohol abuse or drug addiction (for adolescent and adult subjects)~* Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion~* Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided~* Identified as an investigator or employee of the investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural, or adopted child) of the investigator or employee with direct involvement in the proposed study.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Group 1: QIV Lot 1 (Type: EXPERIMENTAL): Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 1.
- Group 2: QIV Lot 2 (Type: EXPERIMENTAL): Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 2.
- Group 3: QIV Lot 3 (Type: EXPERIMENTAL): Participants will receive the Quadrivalent Influenza Vaccine (QIV) from Lot 3.
- Group 4: TIV (Type: ACTIVE_COMPARATOR): Participants will receive the Trivalent Influenza Vaccine (TIV).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete